Date: 2013-03-26
Type of information:
Compound: Nanocyclix® technology
Company: Sanofi (France) Oncodesign (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
licensing
Action mechanism: Nanocyclix® is a proprietary medicinal chemistry technology and research platform based on macrocyclisation chemical methodology and knowledge that gives access to potent and selective kinase inhibitors based on shape complementarity in the ATP binding site of kinases. In this way, unprecedented selectivity is achieved even among kinases with high homology. In addition, the technology allows rapid improvement in the pharmacokinetic properties of the Nanocyclix® leads based on established knowledge.
Disease:
Details: * On March 26, 2013, Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, has announced that it has signed a second research collaboration
agreement with Sanofi. This partnership follows a first agreement signed in summer 2012, relating to a number of kinase targets being developed by Sanofi. This second agreement aims to identify inhibitors of a kinase which plays a key role in tissue protection and repair. Oncodesign will use its Nanocyclix® technology to design and synthesize potent new selective inhibitors. Sanofi will have exclusive licensing rights to the molecules that result from the collaboration. Under the terms of the agreement, Oncodesign will apply its Nanocyclix technology to a key target implicated in the therapeutic area of tissue protection and repair.
Financial terms: The cost of the initial phase of the work is to be met in full by Sanofi, who will have exclusive rights to the results of the program. The financial details have not been disclosed.
Latest news:
